Skip to main content
JAMA Network logoLink to JAMA Network
. 2021 Oct 20;157(10):1246. doi: 10.1001/jamadermatol.2021.4398

Errors in Table 1, Figure 3, and Results

PMCID: PMC8529406  PMID: 34668957

In the Original Investigation titled “Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial,”1 the phrasing of sentences in the Safety section of the Results was corrected, “PP-NRS total score” was changed to “PP-NRS total score, mean (SD)” in Table 1, and 6 superscript letters in Figure 3 were changed from “c” or “d” to “a”. This article was corrected on October 6, 2021.

References

  • 1.Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. Published online August 18, 2021. doi: 10.1001/jamadermatol.2021.2830 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Dermatology are provided here courtesy of American Medical Association

RESOURCES